MindBio Therapeutics Corp., a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, has completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk, the company announced. The new hardware builds on a prototype developed in June and is designed to support MindBio’s proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment.
The completion of manufacturing marks a critical step toward commercialization. MindBio is continuing software integration, system testing and validation of its predictive models against conventional breath alcohol and oral fluid testing methods, with a potential initial commercial pilot targeted for later this year. The company is developing the kiosk as a rapid, non-invasive alternative to conventional drug and alcohol screening, targeting safety-sensitive industries including mining, aviation, construction, heavy transport and law enforcement.
For investors, the announcement signals progress in a niche but potentially high-growth market. MindBio aims to enable more frequent, large-scale workplace screening while potentially reducing testing costs, administration time and operational disruptions. The planned commercial pilot would provide an opportunity to evaluate the technology’s performance in a real-world environment against existing testing methods, a key milestone for regulatory acceptance and customer adoption.
The global push for stricter workplace safety standards, particularly in industries where impairment can have catastrophic consequences, creates a receptive market. Traditional testing methods often require dedicated personnel, specialized equipment and significant time, limiting how often screenings can be conducted. MindBio’s voice-based approach, which uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, could allow employers to screen more frequently and at lower cost.
However, challenges remain. The technology must demonstrate reliability across diverse populations, accents and environmental conditions, and gain acceptance from regulators and unions. The upcoming pilot will be closely watched as a bellwether for the broader adoption of AI-driven impairment detection. If successful, it could open the door to a new standard in workplace safety, with MindBio positioned as an early mover.
MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for a range of enterprise environments including the mining industry, aviation, construction and law enforcement. The latest news and updates relating to MBQIF are available in the company’s newsroom at https://nnw.fm/MBQIF. To view the full press release, visit https://nnw.fm/15cJf.
This article has been disseminated on behalf of MindBio Therapeutics Corp. and may include paid advertising. NetworkNewsWire, a specialized communications platform with a focus on financial news and content distribution, is one of 75+ brands within the Dynamic Brand Portfolio at IBN. The platform provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, and social media distribution to millions of followers. For more information, please see full terms of use and disclaimers on the NetworkNewsWire website at https://www.NetworkNewsWire.com/Disclaimer.
